Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Royalty Pharma plc
RPRX
NASDAQ·Healthcare·Medical - Pharmaceuticals·Mkt cap $24.0B
$57.77
▲ +3.57%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$34.08 - $57.80
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 54.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Diversified portfolio of 35+ marketed therapies reducing concentration risk
- Recurring, predictable royalty revenue streams independent of R&D execution
- Deep industry relationships with academic, biotech, and pharmaceutical partners
- Established deal-sourcing network providing deal flow advantages
- Experienced management team with pharmaceutical and finance expertise
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Moderate growth ahead
Expansion of royalty portfolio through strategic acquisitions
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+14.8% over 3m
Quality
Excellent
Excellent business quality
Dividend
Modest
1.63% yield
Smart-money signal
Who's buying RPRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 5, 2026
MAY 6, 2026
Reported EPS of $1.30 vs $1.22 consensus (+6.6% surprise). Revenue of $925.0M vs $881.7M expected (+4.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+6.6%
Next: Aug 5, 2026
Revenue trend · last 8Q
—
—
-0%
+0%
+8%
+8%
+5%
+11%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$537.3M
$564.7M
$593.6M
$568.2M
$578.7M
$609.3M
$622.0M
$630.6M
Margins · last 8Q
Gross
—
Operating
—
Profit
46.8%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$60.00
▲ +3.9% vs $57.77
Latest: Citi · May 7, 2026
2 analysts covering
vs Industry
How RPRX stacks vs Medical - Pharmaceuticals
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related